Stock Expert AI
Equity research screen

AMGN vs. GILD: Detailed Stock Comparison

This page provides a detailed comparison between Amgen Inc. (AMGN) and Gilead Sciences (GILD). The analysis includes business model considerations relevant to investors interested in the biotechnology sector. This comparison helps to evaluate each company's strengths, weaknesses, and overall investment appeal based on their current market positions.

Quick Answer This page offers an analytical comparison between Amgen (AMGN) and Gilead Sciences (GILD), two significant players in the biotechnology industry. The screen examines their business models and market capitalizations to help investors understand their distinct focuses within pharmaceuticals. Amgen specializes in a wide array of human therapeutics, while Gilead excels in antiviral medications.
Screens40Average score72.00Updated2026-09-03
Data sources: Financial Modeling Prep | Yahoo Finance | SEC Filings 21,000+ US companies analyzed

Amgen (AMGN) vs. Gilead Sciences (GILD): Key Considerations

Amgen and Gilead represent two established companies in the biotechnology space. Amgen focuses on human therapeutics, while Gilead has a strong presence in antiviral medications. Understanding the nuances of each business is key to informed investment decisions in the pharmaceutical industry.

AMGN vs GILD: The Numbers

Side by side on the figures we publish for both companies. Not a ranking and not a recommendation — the same metrics, read off the same source, on the same day.

AMGN and GILD on five published metrics — figures as of 2026-09-11; prices refresh on page view. Source: Financial Modeling Prep, Yahoo Finance.
Metric AMGNAmgen Inc.GILDGilead Sciences
MoonshotScore 8163
Price $382.47$144.81
Change (1D) -2.25%-0.58%
Market cap $206.4B$179.8B
P/E ratio 23.313.6

A dash means we hold no published figure for that company — not a zero. Full analysis: AMGN · GILD.

Shortlist Context

This analysis is designed to provide a high-level overview for investors, and is not a substitute for detailed due diligence. Individual investment decisions should reflect a thorough understanding of personal risk tolerance and financial circumstances.
“MoonshotScore rates a US-listed stock 0 to 100 — higher means stronger numbers. Most carry an older nine-factor score; the rest use five sector-relative pillars, re-ranked daily — common stocks and ADRs only. Funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
— Stock Expert AI published methodology (how MoonshotScore works)

Questions worth resolving before acting on the screen

What are the primary business areas of Amgen and Gilead Sciences?

Amgen focuses on developing and manufacturing human therapeutics for various medical conditions. Gilead Sciences specializes in antiviral drugs, particularly for HIV, liver diseases, and other viral infections.

How do Amgen and Gilead compare in terms of market capitalization?

A comparison of market capitalization provides insight into each company's size and overall market value. Current market conditions and company performance influence these figures.

What factors should investors consider when evaluating biotechnology stocks like AMGN and GILD?

Investors should consider each company's product pipeline, patent protection, regulatory approvals, and market competition. Financial metrics such as revenue growth, profitability, and cash flow are also important.

Where can I find more information about Amgen and Gilead Sciences?

Detailed financial reports, investor presentations, and news releases can be found on each company's investor relations website. Third-party financial analysis and ratings from reputable sources can also provide valuable insights.

Explore More Research

Stock Expert AI provides data and analysis tools for educational purposes. This is not financial advice. Past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. Data sources: Financial Modeling Prep, Yahoo Finance.